• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

nirmatrelvir

Xocova: Powerful New Japanese Pill for Coronavirus Treatment
Posted inCOVID-19, Infections, New Drugs, Regulatory

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

November 27, 2022December 5, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

coronavirus Omicron
Posted inCOVID-19, Infections, Research

Omicron Treatment: Most Effective Drugs

August 31, 2022September 8, 2022

Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

August 24, 2022November 28, 2022

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

Paxlovid (nirmatrelvir + ritonavir).
Posted inCOVID-19, Infections, Research

Paxlovid Works Against Omicron

January 18, 2022September 8, 2022

The newest COVID-19 treatment is highly effective against the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir).
Posted inCOVID-19, Infections, New Drugs, Regulatory

Paxlovid Approved in the U.S.

December 22, 2021September 8, 2022

Pfizer’s oral antiviral drug has entered the world’s main pharmaceutical market.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News